Trial Outcomes & Findings for Coronary Flow Reserve Following Orbital Atherectomy (NCT NCT02339545)

NCT ID: NCT02339545

Last Updated: 2023-07-18

Results Overview

CFR was measured after successful percutaneous coronary intervention (PCI) treatment of severely calcified coronary lesions. It was calculated from coronary blood flow velocity measurements, which were derived from Doppler-velocity wire data recorded in real time. The CFR formula utilized was APVp/APVb, where APVb is the average peak velocity at baseline and APVp is peak hyperemia.

Recruitment status

COMPLETED

Target enrollment

15 participants

Primary outcome timeframe

Intra-procedurally following successful stent placement. Average procedure time 56 minutes.

Results posted on

2023-07-18

Participant Flow

Participant milestones

Participant milestones
Measure
Coronary Flow Reserve
Single arm - all enrolled subjects had successful coronary revascularization via orbital atherectomy and stenting.
Overall Study
STARTED
15
Overall Study
COMPLETED
15
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Coronary Flow Reserve Following Orbital Atherectomy

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Coronary Flow Reserve
n=15 Participants
Single arm - all enrolled subjects had successful coronary revascularization via orbital atherectomy and stenting.
Age, Continuous
70.6 years
STANDARD_DEVIATION 9.3 • n=5 Participants
Sex: Female, Male
Female
2 Participants
n=5 Participants
Sex: Female, Male
Male
13 Participants
n=5 Participants
Race/Ethnicity, Customized
White
14 Participants
n=5 Participants
Race/Ethnicity, Customized
American Indian or Alaska Native
1 Participants
n=5 Participants

PRIMARY outcome

Timeframe: Intra-procedurally following successful stent placement. Average procedure time 56 minutes.

Population: CFR is analyzed per protocol, which may require Doppler measurement in a control vessel in addition to the target vessel. Only subjects where this procedure is followed are included in the data set. The CFR formula is a ratio: APVp/APVb, where APV = average peak velocity (cm/sec). APVb = velocity at baseline and APVp = velocity at peak hyperemia.

CFR was measured after successful percutaneous coronary intervention (PCI) treatment of severely calcified coronary lesions. It was calculated from coronary blood flow velocity measurements, which were derived from Doppler-velocity wire data recorded in real time. The CFR formula utilized was APVp/APVb, where APVb is the average peak velocity at baseline and APVp is peak hyperemia.

Outcome measures

Outcome measures
Measure
All Eligible Subjects
n=8 Participants
All subjects whose Doppler flow measurements facilitated calculation of coronary flow reserve
Coronary Flow Reserve (CFR)
2.23 Ratio
Standard Deviation 0.33

SECONDARY outcome

Timeframe: At 24 hours or at time of hospital discharge, whichever occurred first

Population: MACE is evaluated per protocol, on subjects with successful PCI treatment of severely calcified coronary lesions

MACE: cardiac death, acute myocardial infarction (Q wave or non-Q wave), or target vessel revascularization.

Outcome measures

Outcome measures
Measure
All Eligible Subjects
n=15 Participants
All subjects whose Doppler flow measurements facilitated calculation of coronary flow reserve
Major Adverse Cardiac Events (MACE)
0 participants

Adverse Events

All Enrolled Subjects

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
All Enrolled Subjects
n=15 participants at risk
All subjects who have had successful revascularization by orbital atherectomy and stenting
Cardiac disorders
Cardiac Death
0.00%
0/15 • At 24 hours or at discharge, whichever was earlier.
MACE defined as: Cardiac death, acute myocardial infarction (Q wave or non-Q wave), target vessel revascularization.

Other adverse events

Adverse event data not reported

Additional Information

Clinical Trials Manager

Cardiovascular Systems, Inc.

Phone: 651.259.2500

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: LTE60